For years, cancer research has focused on cataloging the genetic alterations that drive disease. While that work has revealed the complexity of tumors, it has also highlighted a central challenge: not all drivers are equally actionable.
At IDEAYA, that challenge provoked a simple idea: the most powerful therapeutic opportunities may not come from targeting primary drivers alone, but from understanding the dependencies those drivers create.
Advances in tumor sequencing have given us an unprecedented view into cancer’s genetic landscape. The challenge now is translating that complexity into therapies that deliver meaningful and durable benefit for patients.
We focus on understanding how genetic alterations reshape tumor biology and create specific vulnerabilities that can be therapeutically exploited. These tumor vulnerabilities are often not the primary drivers themselves but arise from the way tumor cells adapt to survive. Once we understand that, new opportunities to intervene begin to emerge.
Defining tumor vulnerabilities in molecularly defined cancers
Tumor cells operate within a defined biological context. This creates dependencies on specific pathways and processes that sustain growth and survival. Sometimes, these dependencies take the form of synthetic lethal relationships, where a tumor-specific mutation creates reliance on a second target that can be selectively inhibited. Other times, vulnerabilities arise through metabolic dependencies or epigenetic mechanisms that regulate gene expression and tumor cell behavior.
Together, these dependencies represent a broad set of opportunities to identify and target the processes that tumors require to persist, particularly in molecularly defined cancers where traditional approaches have had limited impact.
From data to mechanism: uncovering actionable targets
Identifying these dependencies requires the ability to interrogate tumor biology at scale. Functional genomics approaches allow us to systematically evaluate how genes and pathways contribute to tumor survival across different genetic contexts. At IDEAYA, we integrate these datasets with both public and proprietary research to uncover novel targets that can be translated into precision cancer therapies.
The critical step is developing a clear understanding of the mechanism of action. Simply identifying a target isn’t enough. We need to understand how perturbing that target alters cellular function, how that effect propagates through the system, and why it should translate into clinical activity in a defined patient population.
Designing therapies to exploit vulnerability
That understanding informs how we design therapies. Structure-based drug design allows for precise optimization of how molecules interact with their targets, while computational approaches help accelerate exploration of chemical space. These methods are most effective when applied alongside a strong understanding of the underlying biology, particularly when working with novel targets. In parallel, advances in therapeutic modalities, including antibody-drug conjugates, provide additional ways to selectively target tumor vulnerabilities and address the drivers of tumor growth and drug resistance.
Tumor heterogeneity and adaptive resistance remain central challenges. Tumors consist of diverse cell populations and can adapt under therapeutic pressure, limiting both the depth and durability of response to therapies. Addressing these challenges requires focusing on vulnerabilities that are fundamental to tumor survival or that constrain the tumor’s ability to evolve. Epigenetic regulation, for example, plays a key role in enabling phenotypic plasticity—the ability of a single genotype to produce multiple, distinct physical, behavioral, or physiological phenotypes in response to varying environmental conditions. Whereas certain lineage-dependent programs, or functions that rely entirely on a cell's developmental history, ancestral origin, or specific biological trajectory, are required to maintain tumor identity.
These insights also inform combination strategies, where targeting complementary mechanisms can limit the pathways available for resistance.
Translating insight into patient impact
Precision oncology succeeds when we can align tumor biology, therapeutic design, and patient selection. By defining vulnerabilities within molecularly defined cancers and developing therapies that exploit those vulnerabilities, treatments can be more effectively matched to the patients most likely to benefit.
As our understanding of tumor biology continues to deepen, new vulnerabilities and novel targets will continue to emerge. At its core, this approach is about moving beyond what tumors are, to understanding what they require to survive—and using that knowledge to design therapies that can meaningfully change outcomes for patients with hard-to-treat cancers.
